Radiance Biopharma secured global rights to a bispecific nanobody antibody-drug conjugate (ADC) targeting c-MET and EGFR, designed for solid tumor treatment, through a $1.165 billion agreement with Novatim Immune Therapeutics. The candidate, in early-phase trials, represents a promising modality in oncology that exploits simultaneous targeting of two tumor markers, with significant milestone and royalty payments potential. The transaction highlights ongoing industry focus on multispecific biologics for challenging solid tumors.